Located in Basel, Switzerland, Medartis develops, manufactures and distributes medical internal fixation devices and surgical instruments offered in system solutions for small bone fractures focusing on the extremities. The company was founded in 1997 by Dr. Thomas Straumann and employs more than 500 people on 12 sites, and its products are marketed in 52 countries.
In recent years, the company has established itself among surgeons and key medical opinion leaders as the developer of the most efficient implant solutions for small bone fractures of the extremities. The implants and instruments exceed rival products in terms of handling, precision and ease of use and this has been reflected in H1 revenue growth of 23% compared to the same period last year.
Medartis has established itself either No. 1 or 2 market position in DACH, France and Australia. Meanwhile, the US market for extremities repairs represents almost half of the global market, thus Medartis is developing its market position in the US by focusing on its business in extremities, in particular on product, services but also medical doctors training.
Back in February 2018 the company announced its plans to go public, and on 23 March successfully listed on the Swiss stock exchange. For the past month Medartis shares have been trading above 60 Swiss Francs per share – an increase of at least 25% in value since the IPO. The proceeds of its successful listing continue to be used to facilitate the company’s expansion and growth. Furthermore, Medartis invests 10% of its revenues in R&D in order to consolidate and drive its innovation leadership forward.
